Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities (2011 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Total Non-Current Liabilities data on file, last reported at $851.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 1.08% year-over-year to $851.1 million; the trailing twelve-month figure through Mar 2026 stood at $851.1 million (up 1.08% YoY), and the FY2025 full-year result was $887.5 million, up 4.39% from the prior year.
• Total Non-Current Liabilities retreated to $851.1 million in Q1 2026, from $887.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $894.3 million in Q3 2025 to a low of $366.7 million in Q1 2022.
• A 5-year average of $600.5 million and a median of $429.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities gained 0.47% in 2024 and soared 104.25% in 2025, its largest moves.
• Tracing ANIP's Total Non-Current Liabilities over 5 years: stood at $420.2 million in 2022, then climbed by 5.2% to $442.0 million in 2023, then soared by 92.34% to $850.2 million in 2024, then grew by 4.39% to $887.5 million in 2025, then slipped by 4.1% to $851.1 million in 2026.
• Business Quant data shows ANIP's Total Non-Current Liabilities at $851.1 million in Q1 2026, $887.5 million in Q4 2025, and $894.3 million in Q3 2025.